Article Versions Notes

Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, et al. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics. 2021; 11(1):138. https://doi.org/10.3390/diagnostics11010138

Santoni, Matteo, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, and et al. 2021. "Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?" Diagnostics 11, no. 1: 138. https://doi.org/10.3390/diagnostics11010138

Santoni, M., Massari, F., Bracarda, S., Procopio, G., Milella, M., De Giorgi, U., Basso, U., Aurilio, G., Incorvaia, L., Martignetti, A., Rizzo, M., Cartenì, G., Grande, E., Matrana, M. R., Crabb, S. J., Vau, N., Sorgentoni, G., Cimadamore, A., Montironi, R., & Battelli, N. (2021). Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics, 11(1), 138. https://doi.org/10.3390/diagnostics11010138